Pfizer Inc. (NYSE:PFE) Shares Purchased by FLC Capital Advisors

FLC Capital Advisors boosted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 22.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 58,490 shares of the biopharmaceutical company's stock after purchasing an additional 10,879 shares during the quarter. FLC Capital Advisors' holdings in Pfizer were worth $1,482,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Pfizer by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company's stock worth $13,756,738,000 after buying an additional 2,285,276 shares during the period. Geode Capital Management LLC boosted its holdings in Pfizer by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company's stock valued at $3,190,131,000 after purchasing an additional 2,923,537 shares during the last quarter. Norges Bank bought a new position in Pfizer during the 4th quarter worth approximately $2,328,986,000. Massachusetts Financial Services Co. MA lifted its holdings in Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after buying an additional 5,350,381 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Pfizer by 7.7% in the 4th quarter. Northern Trust Corp now owns 58,382,560 shares of the biopharmaceutical company's stock worth $1,548,889,000 after purchasing an additional 4,167,222 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently issued reports on PFE. BMO Capital Markets lowered their price target on Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. Jefferies Financial Group raised their target price on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st. TD Cowen reduced their price objective on Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research report on Tuesday, April 22nd. HSBC reduced their price target on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Finally, Citigroup boosted their price target on Pfizer from $23.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of "Hold" and an average target price of $28.55.

Pfizer Stock Down 0.0%

Shares of NYSE PFE traded down $0.01 during mid-day trading on Friday, hitting $24.58. The company had a trading volume of 10,403,584 shares, compared to its average volume of 41,833,607. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $139.72 billion, a PE ratio of 17.82, a price-to-earnings-growth ratio of 0.90 and a beta of 0.58. The firm has a 50-day simple moving average of $24.02 and a two-hundred day simple moving average of $24.75.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the previous year, the business earned $0.82 earnings per share. The business's revenue was down 7.8% compared to the same quarter last year. On average, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.00%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.